Waters Corporation (NYSE:WAT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eighteen analysts that are covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $388.00.
WAT has been the topic of a number of research analyst reports. KeyCorp raised Waters from a "sector weight" rating to an "overweight" rating and set a $460.00 target price on the stock in a report on Monday, March 31st. Baird R W upgraded shares of Waters from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, March 26th. Robert W. Baird boosted their target price on shares of Waters from $355.00 to $374.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 7th. Wall Street Zen raised shares of Waters from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Bank of America boosted their price objective on shares of Waters from $370.00 to $375.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th.
Get Our Latest Research Report on Waters
Waters Stock Performance
Shares of WAT stock traded down $1.70 during trading on Friday, reaching $350.22. The company had a trading volume of 251,699 shares, compared to its average volume of 472,254. The firm's 50 day simple moving average is $349.05 and its two-hundred day simple moving average is $364.25. Waters has a one year low of $279.24 and a one year high of $423.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.81 and a quick ratio of 1.28. The company has a market capitalization of $20.84 billion, a PE ratio of 31.78, a PEG ratio of 3.46 and a beta of 1.10.
Waters (NYSE:WAT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical instruments supplier reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $2.22 by $0.03. The company had revenue of $661.71 million for the quarter, compared to analyst estimates of $655.50 million. Waters had a net margin of 22.02% and a return on equity of 41.70%. The company's quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.21 earnings per share. Sell-side analysts forecast that Waters will post 12.86 earnings per share for the current year.
Institutional Investors Weigh In On Waters
A number of institutional investors have recently added to or reduced their stakes in WAT. Envestnet Portfolio Solutions Inc. lifted its position in shares of Waters by 15.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,587 shares of the medical instruments supplier's stock worth $1,331,000 after buying an additional 482 shares during the period. QRG Capital Management Inc. lifted its holdings in shares of Waters by 85.7% during the first quarter. QRG Capital Management Inc. now owns 1,642 shares of the medical instruments supplier's stock valued at $605,000 after acquiring an additional 758 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Waters by 4.6% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 2,986 shares of the medical instruments supplier's stock valued at $1,101,000 after purchasing an additional 130 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Waters by 4.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 4,813 shares of the medical instruments supplier's stock valued at $1,774,000 after purchasing an additional 189 shares in the last quarter. Finally, CX Institutional bought a new stake in shares of Waters in the 1st quarter worth about $75,000. 94.01% of the stock is owned by institutional investors and hedge funds.
Waters Company Profile
(
Get Free ReportWaters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Stories

Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.